Skip to main content Accessibility help

International price comparisons of Alzheimer's drugs: a way to close the affordability gap

  • Guk-Hee Suh (a1), Anders Wimo (a2), Serge Gauthier (a3), Daniel O'Connor (a4), Manabu Ikeda (a5), Akira Homma (a6), Jacqueline Dominguez (a7) and Bong-Min Yang (a8)...


Background: Alzheimer's drugs are believed to have limited availability and to be unaffordable in low- and middle-income countries compared to high-income countries. The price, availability and affordability of Alzheimer's drugs have not been reported before.

Methods: During 2007 an international survey was conducted in 21 countries in six continents (Argentina, Australia, Brazil, the Dominican Republic, France, India, Japan, Macedonia, Mexico, New Zealand, Nigeria, the Philippines, Portugal, Serbia, South Korea, Switzerland, Taiwan, Thailand, Uganda, the U.K. and the U.S.A.). Prices of Alzheimer's drugs were compared using the affordability index (the total number of units purchasable with one's daily income) derived from purchasing power parity (PPP) converted prices as well as raw prices.

Results: Donepezil is available in all 21 countries, whereas the newer drugs are less available. A 5 mg tablet of branded originator donepezil costs just US$0.26 in India and US$0.31 in Mexico, whereas it costs US$6.64 in the U.S.A. Pricing conditions of rivastigmine, galantamine and memantine appear to be similar to that of donepezil. The cheapest branded originators are from India and Mexico. However, in terms of PPP, Alzheimer's drugs in other low- and middle-income countries are much more expensive than in high-income countries. Most people in low- and middle-income countries cannot afford Alzheimer's drugs.

Conclusions: Alzheimer's drugs, albeit available, are often unaffordable for those who need them most. It is hoped that equitable differential pricing will be applied to Alzheimer's drugs.


Corresponding author

Correspondence should be addressed to: Professor Guk-Hee Suh, MD, PhD, Department of Psychiatry, Hallym University College of Medicine, Hangang Sacred Heart Hospital, 94–200 Yeongdeungpo-Dong, Seoul, 150-030 Korea. Phone: +82-2-2639-5289; Fax: +82-2-2633-5910. Email:


Hide All
Danzon, P. M. and Furukawa, M. F. (2006). Prices and availability of biopharmaceuticals: an international comparison. Health Affairs, 25, 13531362.
Ferri, C. P. et al. (2005). Global prevalence of dementia: a Delphi consensus study. Lancet, 366, 21122117.
International Monetary Fund (2008). World Economic and Financial Surveys. Available at (last accessed 22 August 2008).
Jorm, A. F., Korten, A. E. and Henderson, A. S. (1987). The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatrica Scandinavica, 76, 465479.
Mendis, S. et al. (2007). The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bulletin of the World Health Organization, 85, 279289.
Murray, C. J. L. and Lopez, A. D. (1996) Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Boston: Harvard University Press.
Steinbrook, R. (2007). Closing the affordability gap for drugs in low-income countries. New England Journal of Medicine, 357, 19961999.
Wimo, A., Jönsson, L. and Winblad, B. (2007). An estimate of the total worldwide societal costs of dementia in 2005. Alzheimer's and Dementia, 3, 8191.
World Health Organization (2000). Core Indicators on Country Pharmaceutical Situation. Geneva: WHO Publications.
World Health Organization (2002). The World Health Report 2001 Mental Health: New Understanding, New Hope. Geneva: WHO Publications.
World Health Organization/World Trade Organization (2001). Background Paper for the WHO-WTO Secretariat Workshop on Differential Pricing and Financing of Essential Drugs. Available at (last accessed 22 August 2008).
Yang, B. M., Bae, E. and Kim, J. (2008). Economic evaluation and pharmaceutical reimbursement reform in South Korea's national health insurance. Health Affairs, 27, 179187.



Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed